ReviewVaccines2019
Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges.
Review in Vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers.Frontiers in oncology · 2021Pooled it
- Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.Cancer research and treatment · 2023Trial
- Chemo-metallo nanodrivers for spatiotemporally controlled in situ vaccination.Science advances · 2026Article
- miR-181d coordinates homologous recombination and anti-tumor immune responses in glioblastoma.iScience · 2026Article
- Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review.Breast cancer (Dove Medical Press) · 2026Review
- Efficacy and Safety of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Combined with Chemoimmunotherapy in Locally Advanced Breast Cancer: A Single-Center, Retrospective Pilot Study.Breast cancer (Dove Medical Press) · 2026Article
- Influence of immune checkpoint inhibitor target and timing on combination treatment with antibody-based β-emitting targeted radionuclide therapy across tumor immunogenicity profiles.Frontiers in immunology · 2026Article
- Construction of a novel radioresistance-related signature for prediction of prognosis, immune microenvironment and anti-tumour drug sensitivity in non-small cell lung cancer.Annals of medicine · 2025Article
- MiR-26b-5p mediates radioresistance and immunosuppression via targeting PRKCD in non-small cell lung cancer.Journal of cancer research and clinical oncology · 2025Article
- Genetically engineered Magnesium/Manganese nanoparticles for cancer radioimmunotherapy.Journal of nanobiotechnology · 2025Article
- Gas Plasma Combination Therapies-Promises from Preclinical Oncology Research.Antioxidants (Basel, Switzerland) · 2025Review
- Advancement insights in cancer vaccines: mechanisms, types, and clinical applications.Molecular biology reports · 2025Review
- Advances in radiotherapy enhancing the efficacy of immune checkpoint inhibitors in malignant.Frontiers in oncology · 2025Review
- In Situ Vaccination with Poly-ICLC Combined with Systemic Nivolumab for the Treatment of Unresectable Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Review
- Integrative Approaches in Non-Small Cell Lung Cancer Management: The Role of Radiotherapy.Journal of clinical medicine · 2024Review
- TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis.EMBO molecular medicine · 2024Article
- Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy.Journal of Cancer · 2024Review
- Editorial: The role of radiotherapy in reshaping tumor immune microenvironment.Frontiers in immunology · 2023Article
- Chemical and Synthetic Biology Approaches for Cancer Vaccine Development.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is generally considered to be a local treatment, but there have been reports of rare cases demonstrating abscopal effects in which antitumor effects have been observed in cancer lesions other than the irradiated site. This result is more likely to occur when immune checkpoint inhibitors are used in addition to radiotherapy. Certain radiation-induced chemokines and cytokines have immune-enhancing effects. Immune checkpoint inhibitors may strengthen these effects by stimulating antigen-presenting cells and effector cytotoxic T cells. To date, there is no consensus regarding the applicability of the abscopal effect in the clinical setting, including optimal methods for combining immune checkpoint inhibitors and irradiation. In this review, we highlight the evidence for interactions between cancer immunotherapy and radiotherapy and discuss the potential of such interactions for use in designing novel combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.